Wong D T, Bymaster F P, Engleman E A
Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA.
Life Sci. 1995;57(5):411-41. doi: 10.1016/0024-3205(95)00209-o.
In this review, we describe the evolutionary process involved in the discovery of the selective 5-HT uptake inhibitor, fluoxetine, and summarize some of the large body of scientific research performed on fluoxetine in the 20 years since the first publication. The historical background of the proposed involvement of 5-HT in psychiatric disorders and the activity of tricyclic antidepressants in depression is reviewed. The effects of fluoxetine in various in vitro assays and in animal studies including receptor down-regulation, neurochemical and behavioral models are summarized. In addition, the clinical effectiveness of fluoxetine in depression and obsessive compulsive disorders and its potential use in other disorders are examined.
在本综述中，我们描述了选择性5-羟色胺（5-HT）摄取抑制剂氟西汀的发现所涉及的演变过程，并总结了自首次发表以来20年间对氟西汀进行的大量科学研究。本文回顾了5-HT参与精神疾病的假设的历史背景以及三环类抗抑郁药在抑郁症中的活性。总结了氟西汀在各种体外试验和动物研究中的作用，包括受体下调、神经化学和行为模型。此外，还研究了氟西汀在抑郁症和强迫症中的临床疗效及其在其他疾病中的潜在用途。
